glibenclamide + rosiglitazone

glibenclamide + rosiglitazone is an oral combination therapy comprising two distinct antihyperglycemic agents for the management of type 2 diabetes mellitus. **glibenclamide** is a sulfonylurea that stimulates pancreatic beta cells to increase insulin secretion by closing ATP-sensitive potassium channels, thereby reducing blood glucose. **rosiglitazone** is a thiazolidinedione (TZD) that increases insulin sensitivity in adipose tissue, muscle, and liver by activating the peroxisome proliferator-activated receptor gamma (PPARγ). The combination targets both insulin secretion and sensitivity, providing additive glycemic control for adults with type 2 diabetes inadequately controlled by monotherapy[1][5].

Brand names

None found for the fixed-dose combination of only these two agents (without metformin)

Other names

glyburide + rosiglitazone